Regulatory Approval Risk

Regulatory approval risk is the uncertainty that a signed acquisition or merger will be delayed, conditioned with costly divestitures, or blocked entirely by government regulators assessing competition impacts, national security concerns, or foreign-investment thresholds. It can add 6–18 months to a deal timeline or destroy the transaction entirely.

Why regulation exists and why it matters to deal risk

Modern mergers and acquisitions are subject to scrutiny by antitrust authorities, foreign-investment review boards, sectoral regulators (telecoms, banking, defense), and sometimes political pressure. The purpose of regulation is to protect consumers and national interests; the effect on deal certainty is to create uncertainty.

An acquisition agreement is typically signed months before closing. Between signature and closing, a buyer must satisfy multiple conditions: obtain debt financing, secure key customer retention, and obtain regulatory approval. If any of these fails, the deal terminates. Regulatory approval risk is the risk that the regulator—even after due diligence and a signed agreement—concludes that the deal harms competition or national security and blocks or heavily conditions it.

This risk is not abstract. High-profile deals have been abandoned or restructured after regulators’ objections. The cost is enormous: the buyer has sunk legal and financial advisory fees, management distraction, and opportunity cost; the seller has lost time and market positioning; employees face uncertainty.

Antitrust risk and merger review

The primary regulatory hurdle is antitrust review. In the United States, the FTC and Department of Justice examine whether a merger substantially lessens competition. In the European Union, the European Commission conducts a similar review. Other nations (UK, Canada, Australia, China, India) all have their own merger control regimes.

The standard inquiry is: does the merger create a risk of monopolistic pricing, reduced innovation, or foreclosure (where a combined entity denies rivals access to essential inputs)?

A buyer acquiring a direct competitor in a concentrated market faces high antitrust risk. For example, if a deal would combine the two largest food manufacturers in a small country, regulators may worry that the combined firm could raise prices. If a buyer acquiring a supplier also competes downstream and might refuse to sell supplies to downstream rivals, regulators may see foreclosure risk.

Deals are blocked or heavily conditioned when the competitive harm appears clear and unavoidable. A buyer can mitigate this by offering remedies:

• Divestiture of overlapping product lines or geographies
• Licensing of technology or patents to rivals
• Firewalls preventing information sharing between merged divisions
• Customer commitments guaranteeing continued supply at historical prices

These remedies reduce the competitive threat, but they also shrink the deal’s value. A buyer might pay $5 billion for a competitor, only to divest $1 billion of revenue to satisfy regulators. The deal proceeds, but the economics are diminished.

National security and CFIUS review

Beyond antitrust, a buyer—particularly a foreign buyer—may face national security scrutiny. In the United States, the Committee on Foreign Investment in the United States (CFIUS) reviews foreign acquisitions of businesses that touch sensitive sectors: defense, telecommunications, aviation, semiconductors, energy, biotechnology, and critical infrastructure.

CFIUS does not ask whether the deal is anticompetitive. It asks whether the foreign buyer might compromise US national security. The calculus is political and sometimes opaque. A Chinese buyer acquiring a small chip-design company might sail through; a Chinese buyer acquiring a major semiconductor manufacturer almost certainly will not. A European buyer acquiring a defence contractor faces scrutiny; a Canadian buyer may not.

CFIUS reviews are mandatory for certain sectors and voluntary for others. Buyers in sensitive spaces often request a CFIUS review pre-signature to avoid the uncertainty of post-signature blocking. If a buyer skips CFIUS, obtains regulatory approval for the deal, and then closes the transaction, CFIUS can retroactively order divestiture. The buyer then faces the nightmarish scenario of owning an asset for weeks or months before being forced to sell it.

Deal structure and closing conditions

To manage regulatory risk, acquisition agreements typically include a series of closing conditions:

• The buyer must obtain debt financing
• The target must maintain its business within historical parameters (no major customer losses)
• No material adverse change must occur
• The parties must obtain all necessary regulatory approvals

If a closing condition is not satisfied by a specified deadline, either party can terminate the deal. Regulatory approval deadlines are often set at 12 months, with the option to extend by mutual agreement.

A buyer worried about antitrust risk may negotiate a reverse termination fee: if the buyer fails to obtain regulatory approval due to its own conduct or inaction, it owes the seller a fee (typically 3–4 per cent of enterprise value). This incentivises the buyer to engage with regulators in good faith and prevents the buyer from using antitrust doubt as an excuse to escape a deal it no longer wants.

Foreign investment screening outside the US

The European Union, United Kingdom, Japan, Canada, Australia, and China all have foreign-investment screening regimes. The EU’s approach is newer (as of 2020) and focuses on critical infrastructure, dual-use technology, and supply chains. A non-EU buyer acquiring a leading European chipmaker or telecoms operator faces potential review and conditions.

Some deals are reviewed sequentially in multiple jurisdictions. A US buyer acquiring a target with significant EU operations faces both HSR filing in the US and a separate review by the European Commission. If one regulator blocks, the deal dies. Both must clear, or the buyer and seller must renegotiate.

Timing, certainty, and deal abandonment

Regulatory risk creates three commercial pressures:

1. Timeline risk: A deal expected to close in 3 months extends to 9 months waiting for regulatory clearance. The buyer’s financing commitments may expire. Key employees may leave the target. Customers may switch providers.

2. Certainty risk: Neither party knows if the deal will close until the regulator says so. This is psychologically corrosive. The buyer cannot announce the acquisition to shareholders or begin integration planning. The target’s board cannot tell the market the transaction is definite.

3. Remedy risk: Even if regulators approve, they may impose conditions (divestitures, licensing, firewalls) that degrade the deal’s economics. The buyer must decide whether to accept the remedy or walk away and trigger a reverse termination fee.

In rare cases, regulatory uncertainty is so high that buyers and sellers negotiate a reverse termination right: the seller can terminate the deal if regulatory approval is not obtained by a specified date, without paying a fee. This is most common when the seller initiated the sale (in an auction process) and buyers knew antitrust risk was real from the start.

Recent trends and political economy

Regulatory scrutiny of mergers and acquisitions has intensified in recent years. Antitrust authorities globally have become more sceptical of large deals and more active in pursuing divestitures and conditions. The FTC under recent administrations has challenged several high-profile transactions and shifted its merger guidance to a more interventionist posture.

CFIUS reviews of foreign investment have also widened, particularly for acquisitions by Chinese entities. Political concerns about supply-chain resilience, semiconductor sovereignty, and biosecurity have made deal approval more uncertain.

For deal teams, this means building in longer timelines, hiring antitrust economists early, and structuring the deal to be “regulator-friendly” even if it reduces economic value. A deal that sails through antitrust review—even with small remedies—is often preferable to a deal that carries the sword of Damocles until close.

See also